Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
We would like to commend Kim et al. [1] for conducting the study to explore the activity and safety of romidepsin in patients with relapsed/refractory extranodal natural killer/T-cell lymphoma (ENKTL).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.